🔴#SONDAKİKA | Ulaştığım bilgilere göre İstanbul Emniyet Müdürlüğü Organize Suçlardan sorumlu ekip: Nevzat Aydın'ı tehdit eden ve eylem hazırlığında olan 4 şahsı hücre evinde YAKALADI. (Özel haber) Detaylı bilgiyi birazdan paylaşacağım.

🎙 @montypal of @cityofhope and @RyanNipp of @StephensonCC discuss high-impact research presented at #ASCOQLTY26 on the latest episode of the #ASCODailyNews Podcast: bit.ly/4zg53kt

Dr. Florian Lordick summed it up perfectly at #ESMO26 👏 💡 Surrogate endpoints like PFS and ORR can help bring treatments to patients earlier, but they don’t always translate into better overall survival. 🙏Regulatory acceptance doesn’t necessarily mean clinical validation. An important distinction in oncology! @kbaskurtt @osutcuoglu

💚 So happy to be featured in ESMO’s #ESMOcommunity video at #ESMO26 🌍 💫 More than science, oncology is about people, friendships, and a shared passion for better cancer care. 🙏 Thank you, @myESMO, for including me in this amazing community! @FLordick28391 @YJanjigianMD @MartinReck2 @FAndreMD @osutcuoglu @uyargalip @kbaskurtt #ESMO2026 #Oncology #CancerResearch #MedicalOncology #CancerCare #GlobalOncology #YoungOncologists #Madrid2026

💬 “Every conversation at #ESMO26 can turn into a future project.” Which conversations have had a lasting impact on your professional journey? Share your story using #ESMOconversations and #ESMO26.

Happy to share our new study published in The Oncologist! In patients with de novo mHSPC, baseline 25(OH)D provided prognostic information for progression-free survival and contributed to a prognostic model that was externally validated. 🔗 doi.org/10.1093/oncolo/oyag3… Grateful to all co-authors and collaborators. #ProstateCancer #mHSPC #OncologyAdvances #Oncology @osutcuoglu @kbaskurtt @Xesiloglu @drOrhunakdogan @tubaugurdr @yucelbirkadriye @oncodaily @OncoAlert @OncBrothers @OncoDailyGU @OUPAcademic

I am so excited for @myESMO in Madrid in less than a month. This will be transformational for gynecologic cancers - here is what I am looking forward to in endometrial cancer. 1/ #ESMO26 brings practice-shaping endometrial cancer data, from early-stage dMMR disease to the post-IO setting. A thread on the readouts I'm most excited about 🧵 #gyncsm

Thread 2: Cervix and Ovarian 1/5 Part 2 of my #ESMO26 gyn preview: cervical and ovarian cancer, where ADCs keep multiplying and new pathways are emerging 🧵 #gyncsm

The 3rd Eurasian Interdisciplinary Oncology Congress continues with international participation! Dr. Elizabeth Smyth shares the latest advances in metastatic gastric cancer treatment. @EurasianOnco @osutcuoglu #EurasianInterdisciplinaryOncologyCongress #Oncology #GastricCancer

🤝The #SISAQOL pilot in-person training starts today in Zagreb! Bringing together experts & participants to explore the implementation of SISAQOL recommendations for PROs & HRQoL in cancer #ClinicalTrials. Looking forward to two days of learning & collaboration. #SISAQOLtraining

🔎 What drives better HRQoL with nivolumab + cabozantinib in CheckMate 9ER? This post-hoc mediation analysis shows that improvements in fatigue, pain, dyspnea, cough & emotional well-being explain an important part of the HRQoL benefit vs sunitinib. Fatigue was the largest mediator: 24.0% for EQ-5D & 21.1% for FKSI-FWB. A nice example of moving beyond whether PROs improve to understanding why they improve. 📖 The Oncologist, 2026 #KidneyCancer #RCC #PROs #HRQoL #Oncology #CheckMate9ER @crisbergerot @PauloBergerot @oncodaily @OncoAlert @OncBrothers @OncoDailyIO @osutcuoglu @DrMirallas @Xesiloglu @kbaskurtt

⌚ Can a smartwatch identify high-risk patients after discharge? In STEP-CANCER, ≤3,013 steps/day was linked to 90-day readmission (73% vs 13%) and mortality (47% vs 9%). Congrats to @drOrhunakdogan , @uyargalip and team. Special thanks to @crisbergerot and @realbowtiedoc 🙏

🧴  Does topical diclofenac actually prevent capecitabine-induced hand-foot syndrome in everyday practice? Article 📰 ascopubs.org/doi/pdf/10.1200… Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study A prospective real-world study of 151 patients with colorectal or gastric cancer found that prophylactic 1% topical diclofenac💊 🧴 did not 🚫 prevent clinically significant capecitabine-induced hand-foot syndrome. Grade ≥2 HFS occurred in 16.9% with diclofenac versus 13.8% with active monitoring, with no difference in time to onset or HFS-related dose reductions. Female sex and capecitabine monotherapy were independently associated with grade ≥2 HFS. ➡️ Routine diclofenac prophylaxis is therefore 🙅 not supported. @DrOzanYazc1 @FatihGurlerMD @uyargalip @Xesiloglu @ugur_coskun_ @kbaskurtt @OzetAhmet @nuriyeozdemir71 @osutcuoglu

🎉 Our new study is now published in JCO Global Oncology! 💊🖐️ Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study 🔬 In this prospective, two-center real-world study of 151 patients receiving capecitabine-based therapy, we evaluated prophylactic topical diclofenac for the prevention of clinically significant hand-foot syndrome (HFS). 📊 Grade ≥2 HFS occurred in 16.9% (12/71) with topical diclofenac versus 13.8% (11/80) with active monitoring (OR 1.28; 95% CI, 0.52–3.10; P = .591). 💡 Our findings showed that prophylactic topical diclofenac did not reduce clinically significant HFS or delay its onset in routine clinical practice, adding prospective real-world evidence to this evolving area of supportive oncology. 🙏 Special thanks to our first author, Dr. Orhun Akdoğan(@drOrhunakdogan) and our mentor, Dr. Osman Sütcüoğlu(@osutcuoglu) for their leadership and guidance, and to our entire team(@uyargalip, @kbaskurtt, @yucelbirkadriye) for their valuable contributions. Grateful to be part of this collaboration! 📖 @JCOGO_ASCO | @ASCO 🔗 ascopubs.org/doi/pdf/10.1200… #JCOGlobalOncology #ASCO #Oncology #SupportiveCare #Capecitabine #HandFootSyndrome #RealWorldEvidence @KVanLoonMD @RyanNipp @thenasheffect @IshwariaMD @ASCOPres

⏳ Diego Carlos ⏳ Sidiki Cherif ⏳ Anthony Musaba

Avrasya İnterdisipliner Onkoloji Kongresi Türkiye: 🇹🇷 Azerbaycan: 🇦🇿 Kırgızistan: 🇰🇬 Özbekistan: 🇺🇿 Kazakistan: 🇰🇿 Türkmenistan: 🇹🇲 Kuzey Kıbrıs Türk Cumhuriyeti Avrasya Onkoloji Derneği #Avod #Eti #Etipronot instagram.com/avrasyaonkoloj…

Anadolu’da ve Türkmen Yörük geleneğinde “delikanlı” kadın ve erkek için eşit kullanılır Türkçeye özgü bir terim olan “delikanlı” genç, özü sözü bir, cesur ve delişmen karakterli kadın ve erkekler için kullanılır Günümüzde erksi iklim ile sadece genç erkeklere dair kullanılması sadece kültürel bir modernite sapmasıdır

Drug Costs in Federally Sponsored #Cancer Clinical Trials: A Systematic Review. jamanetwork.com/journals/jam… @JAMA_current @JAMANetwork @JAMAOnc @JAMANetworkOpen #CancerCare #ClinicalTrials #CancerResearch @DrJoeUnger @DrDawnHershman

Fantastic meeting these @ASCO LDP 2026-27 classmates at ASCO HQ , diversified group with amazing skills and leadership qualities! @FunchainMD @VaiaFlorou @Sarbaji85064063 @koshkin85 @gandhi_shipra and many others off twitter !

📢Our multicenter study of HER2-low vs HER2-null advanced gastric cancer is now in @JAMANetworkOpen • 522 patients • HER2-low:↑liver mets,↑CEA, worse ECOG; not independently prognostic Thanks @EduardoTB94 &collaborators @OncoAlert @yekeduz_emre @DrYukselUrun @Ankaratip1945